🔗 Share this article

As America continues making unprecedented revisions to its vaccination guidelines, an unexpected name has surfaced unexpectedly: Høeg, an American of Danish descent physician and public health researcher who rose to prominence by questioning coronavirus shots in the global health crisis and has focused upon alleged fatalities following COVID-19 vaccination in her recent position at the Food and Drug Administration.

Proposed Changes to Pediatric Vaccine Schedule

Health officials were set to unveil radical revisions to the childhood vaccination calendar in December, synchronizing the US with the Danish immunization schedule, sources say – a significant shift that would place the US out of alignment with much of the global community with insufficient data for public health gain. This reveal has been postponed until the next year.

In place of the top vaccines chief, Høeg is scheduled to speak at the meeting. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the office this calendar year.

A Shift at the Agency

Høeg's temporary position could signify a strengthened alliance between the drug and vaccine branches as Dr. Høeg and Dr. Prasad solidify control at the agency – and it signals a renewed priority upon reevaluating previously authorized immunizations at the FDA.

Dr. Høeg has often pushed for discontinuing specific childhood shot schedules in the US so as to align more like Denmark, a society with nationalized medicine and a population roughly the size of the state of Wisconsin.

In her initial comments, she has kept her attention on vaccines – usually the domain of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Doubts Over Expertise

Dr. Høeg has no obvious experience in pharmaceutical research, oversight or leadership, which has been typical for previous heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the commissioner and the vaccine center since spring.

“It seems she lacks to have the necessary background” for overseeing the CDER, stated Jonathan Howard. “She has not conducted a clinical trial. She has no expertise in managing a large organization. She is not an expert in industry regulation.”

Previous directors of CBER would “grasp legal statutes and the underlying principles of medication creation”, said Janet Woodcock. “Objectively, she lacks the kind of background that previous people who headed CBER have had.”

CDER has an enormous portfolio at the agency, Woodcock emphasized.

“Everybody just focuses on the novel medication approvals, but the generic program authorizes a multitude of generic medications. There is also a biologic copycat branch, over-the-counter program and other areas, and all of those have to be managed,” Woodcock noted. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Furthermore, a major leadership aspect to the job, which oversees over 5,000 personnel. “It’s a massive leadership role, if you do it right,” the former official said.

Official Statement and Contentious Programs

Regarding questions about Høeg’s credentials and whether this appointment signifies greater collaboration among regulatory chiefs on immunizations, a spokesperson responded that the “inquiries rely on flawed premises”.

“Her resume is consistent with the functions of her role,” the representative said, noting the time Høeg spent guiding the agency head on “medication safety and regulatory science, including computational safety modeling and immunization monitoring”.

As the temporary head, Høeg takes over the agency head's new fast-track approval initiative, a controversial rapid medication authorization process that reportedly worried her predecessors. “By what process are these drugs being selected for this expedited pathway? Who makes the decisions?” Howard questioned. “There’s a lot of lack of transparency occurring at the agency right now.”

Overall, he remarked, “the agency looks to be trending towards less stringent rules of pharmaceuticals, except for vaccines.”

Public Track Record on Vaccines

Concerning vaccines, Høeg has a more established, if problematic, track record, critics observe. She authored a research paper using non-validated crowd-sourced reports to assess the frequency of heart inflammation after Covid immunization. She consulted for the state of Florida chief medical officer Joseph Ladapo, who was said to have altered data to suggest COVID-19 vaccinations are pose a greater threat than they are.

Among her “desired changes” for the new federal leadership included altering guidelines for new vaccines and discontinuing “unnecessary” vaccines, she remarked following the vote on a podcast. At the FDA, Dr. Høeg has according to sources floated the idea of preventing teenage boys from obtaining COVID-19 vaccinations.

“She’s an complete dogmatist who starts off with her conclusions and works backwards to fit the science in a very deceptive, untruthful fashion,” Dr. Howard said.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg joined other skeptics, {like|